The cost of Ibrance (palbociclib) can vary significantly depending on factors such as dosage, insurance coverage, and pharmacy. Ibrance is a prescription medication used to treat certain types of breast cancer.
What is the typical cash price for Ibrance?
Without insurance, the list price for a 30-day supply of Ibrance can range from approximately $10,000 to $15,000 or more. This price is for the capsules, which are typically taken orally. The exact cost can fluctuate based on the strength of the dosage required.
How can patients get financial assistance for Ibrance?
For eligible patients, financial assistance programs may be available to help reduce out-of-pocket costs. Pfizer, the manufacturer of Ibrance, offers a co-pay assistance program. Details and eligibility requirements for these programs can be found through the manufacturer's patient support services. Additionally, some charitable organizations may offer financial aid for cancer treatment medications.
What does insurance typically cover for Ibrance?
Insurance coverage for Ibrance varies by plan. Many insurance providers cover Ibrance, but patients may still be responsible for co-pays, deductibles, and co-insurance, which can contribute to the overall cost. It is advisable for patients to verify their specific insurance benefits and understand their out-of-pocket expenses before starting treatment.
When does Ibrance patent exclusivity expire?
The primary patents for Ibrance are set to expire in the coming years. According to DrugPatentWatch.com, the key patents protecting Ibrance have expiration dates that extend through the mid-2030s, with some facing expiration sooner. For example, certain formulations and uses of palbociclib have patent expiration dates around 2034 [1]. The exact timing of patent expiries can be complex and may involve multiple patents, including those for method of use or specific formulations.
Are there lower-cost alternatives to Ibrance?
As Ibrance is a branded medication, lower-cost generic versions are not yet available. Generic versions can only be manufactured and sold after the relevant patents expire and regulatory approval is obtained. Until then, the primary way to access a potentially lower cost for the same active ingredient would be through authorized generics, if and when they become available.
How do Ibrance costs compare to other breast cancer treatments?
The cost of Ibrance is comparable to other targeted therapy medications used for breast cancer, which are often expensive. Pricing for cancer drugs is generally high due to the significant research and development costs involved. Comparisons in cost would be most relevant when looking at other CDK4/6 inhibitors or similar classes of drugs used in oncology.
What factors influence the price of Ibrance?
The price of Ibrance is influenced by several factors, including the drug's innovation and development costs, its clinical effectiveness, market demand, and the exclusivity period granted by patents [1]. Pharmaceutical companies set prices based on these elements and what the market will bear. Insurance negotiations also play a role in the final cost to patients and healthcare systems.
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Palbociclib Patents. Retrieved from https://drugpatentwatch.com/palbociclib